Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

496.42USD
1 Sep 2015
Change (% chg)

$-17.08 (-3.33%)
Prev Close
$513.50
Open
$500.86
Day's High
$510.73
Day's Low
$494.30
Volume
352,070
Avg. Vol
247,808
52-wk High
$605.83
52-wk Low
$320.54

REGN.OQ

Chart for REGN.OQ

About

Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product... (more)

Overall

Beta: 0.88
Market Cap(Mil.): $53,244.00
Shares Outstanding(Mil.): 103.69
Dividend: --
Yield (%): --

Financials

  REGN.OQ Industry Sector
P/E (TTM): 127.69 35.92 36.12
EPS (TTM): 4.02 -- --
ROI: 13.10 15.30 14.76
ROE: 16.14 15.87 15.63
Search Stocks

Sanofi, Regeneron say new cholesterol drug data positive

PARIS - Sanofi and Regeneron Pharmaceuticals said on Tuesday that a study into their new cholesterol-lowering drug, Praluent, showed promising results.

9:42am EDT

Sanofi, Regeneron say new cholesterol drug data positive

PARIS, Sept 1 - Sanofi and Regeneron Pharmaceuticals said on Tuesday that a study into their new cholesterol-lowering drug, Praluent, showed promising results.

9:35am EDT

Sanofi teams up with Evotec, Apeiron to develop immuno-oncology pills

PARIS - Sanofi is teaming up with Germany's Evotec and Austrian biotech firm Apeiron Biologics to develop a new type of immune system-boosting cancer medicine that could be given as tablets to fight both solid tumors and blood cancers.

10 Aug 2015

Sanofi teams up with Evotec, Apeiron to develop immuno-oncology pills

PARIS, Aug 10 - Sanofi is teaming up with Germany's Evotec and Austrian biotech firm Apeiron Biologics to develop a new type of immune system-boosting cancer medicine that could be given as tablets to fight both solid tumours and blood cancers.

10 Aug 2015

Drugmaker Regeneron's revenue jumps on Eylea sales

Aug 4 - Regeneron Pharmaceuticals Inc reported a 50 percent rise in quarterly revenue, boosted by increasing demand for its blockbuster eye drug, Eylea.

04 Aug 2015

What to Watch in the Day Ahead - Tuesday, August 4

Media company and theme park operator Walt Disney Co is expected to report third-quarter profit above analysts' average estimate. Disney's quarterly results will include gains from the release of second film in the Avengers series, "The Avengers: Age of Ultron". The company is also expected to rake in higher revenue in its park and resorts business unit, helped by the onset of summer break in June. However, Walt Disney's reliance on revenue generated by its cable channels, especially ESPN, remai

03 Aug 2015

What to Watch in the Week Ahead and on Monday, August 3

Next week brings another crush of earnings reports, though as we've turned the corner and are now more than halfway through, the outcome of the season has sort of coalesced in the minds of many - tech, industrials and global-focused companies are having a harder time of it than the financials and healthcare names. Next week brings staples and stalwarts like Disney, expected to keep raking in the bucks just six months before Star Wars starts the entire process over again. But we also have to cont

31 Jul 2015

Sanofi links with Regeneron in $2.2 billion cancer drug push

- French drugmaker Sanofi said on Tuesday it was committing up to $2.17 billion to a collaboration with its long-time partner Regeneron Pharmaceuticals in the hot area of cancer immunotherapy.

28 Jul 2015

Sanofi links with Regeneron in $2.2 bln cancer drug push

July 28 - French drugmaker Sanofi said on Tuesday it was committing up to $2.17 billion to a collaboration with its long-time partner Regeneron Pharmaceuticals in the hot area of cancer immunotherapy.

28 Jul 2015

BRIEF-Sanofi to invest $2.17 bln in Regeneron cancer therapy collaboration

* Sanofi and Regeneron agree to jointly develop PD-1 and other new immuno-oncology antibodies -

28 Jul 2015

Competitors

  Price Chg
Novartis AG (NOVN.VX) CHF91.70 -3.00
Pfizer Inc. (PFE.N) $31.36 -0.86
Bayer AG (BAYGn.DE) €117.05 -3.90
Bayer AG (BAYE.F) -- --
Abbott Laboratories (ABT.N) $43.57 -1.72
Sanofi SA (SASY.PA) €86.00 --
Merck & Co., Inc. (MRK.N) $52.53 -1.32
Amgen, Inc. (AMGN.OQ) $147.46 -4.32
Roche Holding Ltd. (ROG.VX) CHF257.40 -6.60
Eli Lilly and Co (LLY.N) $79.80 -2.55

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks